The move comes after the Sweden-based orthobiologic producer announced plans to develop its own US-based distribution network, which includes cancelling its distribution agreement with Zimmer Biomet.
“Today’s announcement highlights the importance of Bonesupport taking control of its commercial platform in the US. The evaluation of potential distribution partners is progressing to plan. We expect to have a strong coverage of the US market in place in late October, positioning us to create more direct and stronger relationships with our US customer base. This enhanced commercial platform will allow us to successfully market our highly differentiated products, particularly Cerament G, which we aim to launch in the US market in 2021,” CEO Emil Billbäck said in a press release.
BoneSupport said that its in-market sales of Cerament in the US are “continuing to show good growth” with increasing demand which is being met by Zimmer Biomet’s current inventory.
The company specified that Zimmer Biomet will retain the rights to sell and distribute Cerament BVF exclusively until October 2018, and non-exclusively until April 20, 2019.
Last month, BoneSupport announced plans to expand its sales force, adding an additional 13 sales representatives in “key markets” this year.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.